Abstract
This study investigates the ethical challenges
faced by Taiwan’s venture capital (VC) industry when investing in biotechnology
companies and proposes mechanisms to address these issues. Using a literature
review, case analysis, and expert interviews, the study identifies dilemmas
such as information asymmetry, uncertainty, and conflicts of interest. Findings reveal that excessive pursuit of profits
often leads VC firms to overlook social responsibilities, increasing ethical
risks and harming industry reputation. To mitigate this, the study recommends
that VC firms establish dedicated ethical committees to audit risks and provide
guidance. It also suggests creating investment guidelines to define acceptable
practices and integrating ethics, morality, and legal compliance education into
the biotechnology sector. These
recommendations aim to help Taiwan’s VC industry effectively address ethical
challenges, enhance social responsibility, and support sustainable industry
growth.
JEL classification numbers: G24, D70, O35.
Keywords: Venture
capital firms, Biotech start-ups, Ethical decision-making, Expert in-depth interviews.